Emergence of untreatable, multidrug-resistant HIV-1 in patients failing second-line therapy in Kenya

被引：14

作者：

Inzaule, Seth C. ^{[1
,2
,3
]}

Hamers, Raph L. ^{[1
,2
,4
]}

Mukui, Irene ^{[5
]}

Were, Kennedy ^{[3
]}

Owiti, Prestone ^{[3
]}

Kwaro, Daniel ^{[3
]}

de Wit, Tobias F. Rinke ^{[1
,2
]}

Zeh, Clement ^{[6
]}

机构：

[1] Acad Med Ctr, Dept Global Hlth, Amsterdam, Netherlands

[2] Amsterdam Inst Global Hlth & Dev, Pietersbergweg 17, NL-1105 BM Amsterdam, Netherlands

[3] Kenya Govt Med Res Ctr, Kisumu, Kenya

[4] Univ Amsterdam, Acad Med Ctr, Div Infect Dis, Dept Internal Med, Amsterdam, Netherlands

[5] Natl AIDS & STI Control Programme, Nairobi, Kenya

[6] US Ctr Dis Control & Prevent, Kisumu, Kenya

来源：

AIDS | 2017年 / 31卷 / 10期

关键词：

ANTIRETROVIRAL DRUG-RESISTANCE; ADULTS;

D O I：

10.1097/QAD.0000000000001500

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

We performed a countrywide assessment of HIV drug resistance among 123 patients with virological failure on second-line antiretroviral therapy (ART) in Kenya. The percentage of patients harbouring intermediate-to-high-level resistance was 27% for lopinavir-ritonavir, 24% for atazanavir-ritonavir and 7% for darunavir-ritonavir, and 25% had complete loss of activity to all available first and second-line drugs. Overall, one in four patients failing second-line ART have completely exhausted available antiretrovirals in Kenya, highlighting the need for increased access to third-line drugs.

引用

页码：1495 / 1498

页数：4

共 22 条

[21] Virological response, HIV-1 drug resistance mutations and genetic diversity among patients on first-line antiretroviral therapy in N'Djamena, Chad: Findings from a cross-sectional study
Adawaye C.
Fokam J.
Kamangu E.
Alio H.M.
Chahad A.M.
Susin F.
Moussa A.M.
Bertin T.H.-Z.
Tidjani A.
Vaira D.
Moutschen M.
BMC Research Notes, 10 (1)
[22] Body composition and metabolic outcomes after 96 weeks of treatment with ritonavir-boosted lopinavir plus either nucleoside or nucleotide reverse transcriptase inhibitors or raltegravir in patients with HIV with virological failure of a standard first-line antiretroviral therapy regimen: a substudy of the randomised, open-label, non-inferiority SECOND-LINE study
Boyd, Mark A.
Amin, Janaki
Mallon, Patrick W. G.
Kumarasamy, Nagalingeswaran
Lombaard, Johan
Wood, Robin
Chetchotisakd, Ploenchan
Phanuphak, Praphan
Mohapi, Lerato
Azwa, Iskandar
Belloso, Waldo H.
Molina, Jean-Michel
Hoy, Jennifer
Moore, Cecilia L.
Emery, Sean
Cooper, David A.
LANCET HIV, 2017, 4 (01): : E13 - E20

← 1 2 3 →